Two Sigma Investments
NRSN icon

Two Sigma Investments’s NeuroSense Therapeutics NRSN Stock Holding History

Two Sigma Investments’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.6K Sell
44,445
-7,100
-14% -$6.34K ﹤0.01% 4489
2025
Q4 		$39.6K Buy
51,545
+30,459
+144% +$32.1K ﹤0.01% 3957
2025
Q3 		$26.4K Buy
+21,086
New +$30.9K ﹤0.01% 3582

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Two Sigma Investments's NRSN Position: Q1 2026 in Review

Two Sigma Investments reduced its NeuroSense Therapeutics (NRSN) stake by 14% in Q1 2026, selling an estimated $6.34K and leaving 44,445 shares worth $33.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4489.

Two Sigma Investments first reported a position in NRSN in Q3 2025 and has held it in 3 quarters since. The position peaked at $39.6K in Q4 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

  • Two Sigma Investments held 44,445 shares of NeuroSense Therapeutics worth $33.6K as of Q1 2026.
  • Two Sigma Investments sold 7,100 NeuroSense Therapeutics shares in Q1 2026, an estimated $6.34K.
  • NeuroSense Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4489 holding.
  • Two Sigma Investments first reported a position in NeuroSense Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Two Sigma Investments's NeuroSense Therapeutics position peaked at $39.6K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.